fibronectin type III domain containing 7Genealiases: []
Q-omics provides the consensus-scored FNDC7 profile across patient tissues and cancer cell-line models. FNDC7 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FNDC7 is differentially expressed in 5, with the highest sampling consensus in CHOL. Additionally, FNDC7 RNA expression shows 12,308 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, CHOL, and TGCT as cancer lineages where FNDC7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FNDC7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FNDC7 survival associations across molecular data types. FNDC7 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FNDC7 RNA expression–survival associations across cancer types. High FNDC7 expression shows unfavorable associations in KIRC, KICH, LGG, LUAD and UCEC, but favorable associations in PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FNDC7 RNA expression.
This table summarizes FNDC7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in CHOL for RNA.
This table ranks reproducible tumor–normal expression differences for FNDC7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FNDC7 shows lower tumor expression in KICH and higher tumor expression in CHOL, COAD, THCA and HNSC. The CHOL box plot shows higher FNDC7 RNA expression in tumor versus normal tissue (log2 FC = +0.118, t-test p = .020).
This table shows molecular features associated with FNDC7 in patient tissues and cancer cell lines. In patient samples, FNDC7 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, FNDC7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in OVARY and LARGE_INTESTINE.
